June 2009 Volume 6 Number 6
Visit Nature Reviews Cardiology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=50&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Cardiology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=16&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=27&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cardiology Impact Factor: 4.743*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
UCSD Clinical and Translational Research Institute and Nature Medicine
present:
Frontiers of Clinical Investigation Symposium
Metabolism 2009: From Bench to Bedside
October 8-10, 2009
La Jolla, California, USA
The theme for this year's symposium explores innovative approaches to
bridge laboratory investigation to clinical research in metabolism.
Early Bird Deadline: September 8, 2009
Abstract Submission: Deadline: August 21, 2009
For more information visit:
http://links.ealert.nature.com/ctt?kn=81&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Doubts about ventricular reconstruction
Valentin Fuster
p383 | doi:10.1038/nrcardio.2009.78
http://links.ealert.nature.com/ctt?kn=17&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Prevention: Prophylactic statin therapy in the management of cardiovascular
disease
p385 | doi:10.1038/nrcardio.2009.61
http://links.ealert.nature.com/ctt?kn=25&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Statins reduce risk of VTE
p386 | doi:10.1038/nrcardio.2009.66
http://links.ealert.nature.com/ctt?kn=83&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Prevention: Polycap reduces CVD risk
p386 | doi:10.1038/nrcardio.2009.71
http://links.ealert.nature.com/ctt?kn=70&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Antiplatelet therapy: Low-dose aspirin for CVD prevention
p387 | doi:10.1038/nrcardio.2009.69
http://links.ealert.nature.com/ctt?kn=92&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Atrial fibrillation: Stroke risk reduced with clopidogrel plus aspirin
in patients with AF
p387 | doi:10.1038/nrcardio.2009.72
http://links.ealert.nature.com/ctt?kn=3&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Cardiomyopathy: LAMP2 cardiomyopathy insights
p388 | doi:10.1038/nrcardio.2009.67
http://links.ealert.nature.com/ctt?kn=51&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Intervention: Growing new heart muscle cells
p388 | doi:10.1038/nrcardio.2009.68
http://links.ealert.nature.com/ctt?kn=66&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Heart failure: Racial differences in HF among young adults
p389 | doi:10.1038/nrcardio.2009.62
http://links.ealert.nature.com/ctt?kn=80&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Hypertension: Pulmonary hypertension and HF with preserved EF
p389 | doi:10.1038/nrcardio.2009.64
http://links.ealert.nature.com/ctt?kn=32&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Rethinking revascularization
p389 | doi:10.1038/nrcardio.2009.65
http://links.ealert.nature.com/ctt?kn=73&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Hypertension: RF ablation of renal nerves
p390 | doi:10.1038/nrcardio.2009.63
http://links.ealert.nature.com/ctt?kn=7&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Strategies to reduce cardiovascular risk
p390 | doi:10.1038/nrcardio.2009.70
http://links.ealert.nature.com/ctt?kn=88&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Coronary artery disease: Platelet activity: an obstacle for successful PCI
Meinrad Gawaz and Tobias Geisler
p391 | doi:10.1038/nrcardio.2009.76
Dual antiplatelet therapy with aspirin and clopidogrel is effective in
limiting adverse coronary thromboischemic events in most patients undergoing
coronary stenting. However, platelet reactivity to clopidogrel is variable
and stent thrombosis can occur suddenly and unexpectedly in up to 3% of
patients. Is responsiveness to clopidogrel an indicator of risk of
post-treatment thromboischemic events?
http://links.ealert.nature.com/ctt?kn=87&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?
Jose Luis Ferreiro and Dominick J. Angiolillo
p392 | doi:10.1038/nrcardio.2009.60
Proton-pump inhibitors (PPIs) can alter the pharmacodynamic profile of
clopidogrel and reduce its platelet-inhibitory effects. Ho and colleagues
have reported that concurrent use of PPIs and clopidogrel leads to in an
increase in adverse cardiovascular outcomes. In this article we discuss the
clinical implications of the interaction between these two drugs.
http://links.ealert.nature.com/ctt?kn=46&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
A risk score for AF-burning the haystack to find the needle
Ron Pisters and Harry J. Crijns
p394 | doi:10.1038/nrcardio.2009.74
The novel risk score for new-onset atrial fibrillation proposed by Schnabel
et al. is based on readily identifiable risk factors and provides an
excellent 'first draft' to focus primary prevention and halt the pandemic
spread of this arrhythmia and its potentially lethal consequences. The risk
score does, however, require further validation and sophistication with
novel imaging techniques before it can be applied in clinical practice.
http://links.ealert.nature.com/ctt?kn=36&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Stroke: Improving characterization of childhood cerebral arteriopathies
Jose Biller
p395 | doi:10.1038/nrcardio.2009.73
There is notable variation in incidence, presentation, risk factors, and
prognosis for strokes occurring in children. At present, there is no
stroke classification system specifically tailored to the multiple risk
factors and etiologies of pediatric stroke. The study by the International
Pediatric Stroke Study investigators on predictors of cerebral arteriopathy
in children with arterial ischemic stroke deserves special attention in
planning secondary stroke prevention strategies in this population of
patients.
http://links.ealert.nature.com/ctt?kn=78&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Coronary artery disease: Complex coronary disease in the post-SYNTAX era
Giuseppe Tarantini
p397 | doi:10.1038/nrcardio.2009.75
Should patients with high-risk coronary artery disease be treated with
CABG or receive drug-eluting stents? The SYNTAX trial aimed to define the
optimal revascularization strategy for patients with previously untreated
three-vessel and/or left main coronary artery disease.
http://links.ealert.nature.com/ctt?kn=53&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Obesity, inflammation, and atherosclerosis
Viviane Z. Rocha and Peter Libby
Published online: 28 April 2009
p399 | doi:10.1038/nrcardio.2009.55
In this timely Review, Drs Rocha and Libby discuss the commonalities in
the pathophysiology of atherosclerosis and obesity, with a particular focus
on inflammation-an important aspect of both diseases. The authors also
examine the clinical implications of the mechanistic links between the two
conditions.
Abstract: http://links.ealert.nature.com/ctt?kn=94&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=56&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Role for TNF in atherosclerosis? Lessons from autoimmune disease
Gayle E. McKellar, David W. McCarey, Naveed Sattar and Iain B. McInnes
Published online: 07 May 2009
p410 | doi:10.1038/nrcardio.2009.57
Pathways associated with inflammation are thought to account for increased
vascular risk in patients with chronic inflammatory diseases. This Review
summarizes key epidemiologic, physiologic and model data that implicate
involvement of tumor necrosis factor, a pivotal cytokine in the inflammatory
cascade, in atherosclerosis.
Abstract: http://links.ealert.nature.com/ctt?kn=41&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=31&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
MicroRNAs and cardiac pathology
Michael V. G. Latronico and Gianluigi Condorelli
Published online: 12 May 2009
p418 | doi:10.1038/nrcardio.2009.56
The important functional roles of non-protein-coding RNA have come to
light since the discovery of the enzymatic activity of RNA in the mid 1980s.
This Review discusses what is currently known about the role of a class of
non-protein-coding RNA called microRNAs in the heart. Since the first report
on this topic was published in 2005, intense research has been conducted
to elucidate how microRNAs are involved in cardiovascular physiology and
pathology.
Abstract: http://links.ealert.nature.com/ctt?kn=75&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=15&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Cardiac sympathetic activity in stress-induced (Takotsubo) cardiomyopathy
Abhiram Prasad, Malini Madhavan and Panithaya Chareonthaitawee
p430 | doi:10.1038/nrcardio.2009.51
Prasad and colleagues report on the novel technique of 11C hydroxyephedrine
PET imaging for the measurement of myocardial sympathetic neuronal activity
in a patient with stress (Takotsubo) cardiomyopathy.
Abstract: http://links.ealert.nature.com/ctt?kn=38&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=40&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Medical imaging: the radiation issue
Andrew J. Einstein
p436 | doi:10.1038/nrcardio.2009.53
Increases in the doses of ionizing radiation to Western populations have
largely been driven by growth in the use of medical imaging tests, such
as invasive coronary angiography and cardiovascular CT. Here, Dr. Einstein
discusses the association between radiation dose and cancer risk, which
has been the source of some controversy, and highlights the clinical
implications of radiation exposure from imaging tests.
Abstract: http://links.ealert.nature.com/ctt?kn=2&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=89&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Reviews Goes Clinical!
In April 2009, Nature Clinical Practice Rheumatology was completely
redesigned and became Nature Reviews Rheumatology, bringing all the
qualities of the top-ranked* life science review series to the clinical
sciences.
For more information visit:
http://links.ealert.nature.com/ctt?kn=91&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
*2007 Journal Citation Report (Thomson Reuters, 2008)
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=12&m=33218107&r=MTc2NDI1MzEzNAS2&b=2&j=NTAyNTYzNDgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
